Diflucortolone valerate. Asian experience.
More than 10 years ago, diflucortolone valerate (Nerisone, Nerisona) was introduced in Germany and soon after in Asian countries in a concentration of 0.1% in cream, ointment and fatty ointment bases. 897 patients were included in the first Southeast Asian multicentre trial with these 3 formulations, and good efficacy and tolerability combined with a rapid onset of effect were shown. These results were confirmed later in Indonesia in an extended follow-up trial which included 1295 patients. A combination of 0.1% diflucortolone valerate with 1.0% chlorquinaldol was introduced after a multicentre Southeast Asian trial involving 8668 patients with inflammatory or allergic skin conditions for which a supplementary anti-infective treatment, for prophylaxis or therapy, was considered to be indicated. Excellent results were obtained in terms of efficacy, tolerability and cosmetic properties. A randomised double-blind trial comparing this preparation with a so-called 'shotgun' combination containing 0.05% betamethasone 17-valerate, 0.1% gentamicin, 1.0% tolnaftate and 1.0% clioquinol in 288 patients in the Philippines resulted in a better efficacy for the diflucortolone preparation in the 80 patients with bacterially or mycotically infected skin diseases. A 0.3% concentration of diflucortolone valerate was developed and introduced as a high potency topical corticosteroid. A trial in the Philippines which involved 143 patients with mostly severe chronic recurrent and resistant corticosteroid-responsive skin disease confirmed a pronounced clinical efficacy with a low incidence of side effects. For the treatment of inflammatory or eczematised dermatomycosis. 0.1% diflucortolone was combined with 1.0% isoconazole nitrate (Travocort). In a randomised double-blind study of 294 patients in Thailand, this preparation was compared with a plain 1.0% clotrimazole formulation. The results were significantly better for the diflucortolone plus isoconazole nitrate combination in terms of remission of symptoms, and after 1 week the mycological cure rates were also better, as shown in potassium hydroxide and culture investigations. It is concluded, therefore, that diflucortolone valerate in the available galenic bases and in effective combinations with other agents has been proven in extensive clinical trials to be a valuable therapeutic tool in dermatological practice.
Hoppe
G
G
Far East Scientific Office and Clinical Research Centre, Makati, Manila, Philippines.
D001208:Asia; D002750:Chlorquinaldol / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy / Q000382:microbiology; D004060:Diflucortolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005448:Fluocortolone / Q000031:analogs & derivatives*; D006801:Humans; D008825:Miconazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D009824:Ointments; D012871:Skin Diseases / Q000188:drug therapy*
D009824:Ointments; C013486:diflucortolone valerate; D005448:Fluocortolone; D008825:Miconazole; D002750:Chlorquinaldol; C020382:isoconazole; D004060:Diflucortolone